1
|
Yan X, Xu K, Xu Z, Shi C, Lai B, Wu H, Yang S, Sheng L, Wang K, Zheng Y, Ouyang G, Yang D. GLYR1 transcriptionally regulates PER3 expression to promote the proliferation and migration of multiple myeloma. Genomics 2024; 116:110846. [PMID: 38642856 DOI: 10.1016/j.ygeno.2024.110846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 04/06/2024] [Accepted: 04/11/2024] [Indexed: 04/22/2024]
Abstract
Period circadian regulator 3 (PER3) functions as a tumor suppressor in various cancers. However, the role of PER3 in multiple myeloma (MM) has not been reported yet. Through this study, we aimed to investigate the potential role of PER3 in MM and the underlying mechanisms. RT-qPCR and western blotting were used to determine the mRNA and protein expression levels of PER3. Glyoxylate reductase 1 homolog (GLYR1) was predicted to be a transcription factor of PER3. The binding sites of GLYR1 on the promoter region of PER3 were analyzed using UCSC and confirmed using luciferase and chromatin immunoprecipitation assays. Viability, apoptosis, and metathesis were determined using CCK-8, colony formation, TUNEL, and transwell assays. We found that PER3 expression decreased in MM. Low PER3 levels may predict poor survival rates; PER3 overexpression suppresses the viability and migration of MM cells and promotes apoptosis. Moreover, GLYR1 transcriptionally activates PER3, and the knockdown of PER3 alleviates the effects of GLYR1 and induces its malignant behavior in MM cells. To conclude, GLYR1 upregulates PER3 and suppresses the aggressive behavior of MM cells, suggesting that GLYR1/PER3 signaling may be a potential therapeutic target for MM.
Collapse
Affiliation(s)
- Xiao Yan
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China.
| | - Kaihong Xu
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China
| | - Zhijuan Xu
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China
| | - Cong Shi
- Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China
| | - Binbin Lai
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China
| | - Hao Wu
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China
| | - Shujun Yang
- Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China; Laboratory of Stem Cell Transplantation, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China
| | - Lixia Sheng
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China
| | - Keting Wang
- Health Science Center, Ningbo University, Ningbo 315000, China
| | - Yuhan Zheng
- Health Science Center, Ningbo University, Ningbo 315000, China
| | - Guifang Ouyang
- Department of Haematology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, China; Ningbo Clinical Research Center for Hematologic malignancies, Ningbo 315000, China.
| | - Di Yang
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
| |
Collapse
|
2
|
Dai Y, Han B, Dong L, Zhao J, Cao Y. Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. Trends Analyt Chem 2020. [DOI: 10.1016/j.trac.2020.115965] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
Montefiori M, Pilotto S, Marabelli C, Moroni E, Ferraro M, Serapian SA, Mattevi A, Colombo G. Impact of Mutations on NPAC Structural Dynamics: Mechanistic Insights from MD Simulations. J Chem Inf Model 2019; 59:3927-3937. [PMID: 31408337 DOI: 10.1021/acs.jcim.9b00588] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
NPAC is a cytokine-like nuclear factor involved in chromatin modification and regulation of gene expression. In humans, the C-terminal domain of NPAC has the conserved structure of the β-hydroxyacid dehydrogenases (β-HAD) protein superfamily, which forms a stable tetrameric core scaffold for demethylase enzymes and organizes multiple sites for chromatin interactions. In spite of the close structural resemblance to other β-HAD family members, the human NPAC dehydrogenase domain lacks a highly conserved catalytic lysine, substituted by a methionine. The reintroduction of the catalytic lysine by M437 K mutation results in a significant decrease of stability of the tetramer. Here, we have computationally investigated the molecular determinants of the functional differences between methionine and lysine-containing NPAC proteins. We find that the single mutation can determine strong consequences in terms of dynamics, stability, and ultimately ability to assemble in supramolecular complexes: the higher stability and lower flexibility of the methionine variant structurally preorganizes the monomer for tetramerization, whereas lysine increases flexibility and favors conformations that, while catalytically active, are not optimal for tetrameric assembly. We combine structure-dynamics analysis to an evolutionary study of NPAC sequences, showing that the methionine mutation occurs in a specifically flexible region of the lysine-containing protein, flanked by two domains that concentrate most of the stabilizing interactions. In our model, such separation of stability nuclei and flexible regions appears to favor the functional innovability of the protein.
Collapse
Affiliation(s)
| | - Simona Pilotto
- Department of Biology and Biotechnology , University of Pavia , Via Ferrata 9 , 27100 Pavia , Italy
| | - Chiara Marabelli
- Department of Biology and Biotechnology , University of Pavia , Via Ferrata 9 , 27100 Pavia , Italy
| | | | | | - Stefano A Serapian
- University of Pavia , Department of Chemistry , V.le Taramelli 12 , 27100 Pavia , Italy
| | - Andrea Mattevi
- Department of Biology and Biotechnology , University of Pavia , Via Ferrata 9 , 27100 Pavia , Italy
| | - Giorgio Colombo
- ICRM-CNR , Via Mario Bianco 9 , 20131 Milano , Italy.,University of Pavia , Department of Chemistry , V.le Taramelli 12 , 27100 Pavia , Italy
| |
Collapse
|